Statement regarding Omicron Subvariants
11/21/22 Update: The CDC has reported a rapid increase in the circulation of certain COVID-19 variants in the US that are known to be ineffective to several monoclonal antibody (mAb) therapies for the prevention and treatment of COVID-19. Stanford Health Care has been monitoring these variants of concern within our geographic region and has decided we will no longer offer:
- Evusheld for pre-exposure prophylaxis (effective 11/23/22)
- Bebtelovimab for treatment (effective 11/21/22)
At this time, we highly encourage you to stay updated with the latest COVID-19 boosters and take necessary precautions (e.g. masking in public indoor areas) to avoid exposure.
If you develop COVID-19, please inform your healthcare provider and fill out the SHC treatment self-referral form below. There are several therapeutics that are still active against these resistant subvariants and are available (Paxlovid and remdesivir). A member of the COVID Outpatient Therapeutics team will contact you for the best options for COVID-19 treatment. Thank you for understanding.
The SHC COVID-19 Outpatient Therapeutics Team